

**Corrigendum to “PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[ $\alpha$ ]indene Derivative in Lung Cancer Cells [Translational Oncology 7 (2014) 256–266.e5]**



**Kumar Sanjiv<sup>\*,†</sup>, Chi-Wei Chen<sup>‡,§</sup>,  
Rajesh Kakadiya<sup>§</sup>, Satishkumar Tala<sup>§</sup>,  
Sharda Suman<sup>§</sup>, Ming-Hsi Wu<sup>§</sup>, Yen-Hui Chen<sup>§</sup>,  
Tsann-Long Su<sup>\*,§,||</sup> and Te-Chang Lee<sup>\*,‡,||</sup>**

\*Molecular Medicine Program, Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan;

<sup>†</sup>Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan; <sup>‡</sup>Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan; <sup>§</sup>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; <sup>||</sup>Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung, Taiwan

The authors mistakenly placed the figure of body weight change in mice treated with different agents in A549 cells (Supporting information Figure W4,B) with that of H460 cells (Supporting


information Figure W4,A). The corrected Supporting information Figure W4 is attached below.

Address all correspondence to: Te-Chang Lee, PhD or Tsann-Long Su, PhD, Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.  
E-mail: [bmtcl@ibms.sinica.edu.tw](mailto:bmtcl@ibms.sinica.edu.tw)

© 2016 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1936-5233/17

<http://dx.doi.org/10.1016/j.tranon.2016.12.010>



**Figure W4.** Body weight changes in tumor-bearing mice treated with BO-1509, LY294002, or the combination of BO-1509 and LY294002. A, H460 cells; B, A549 cells; C, PC9 cells, and D, PC9/gef B4.